Study identifier:D3720C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Community-Acquired Bacterial Pneumonia, Lung Infection of Individual not Recently Hospitalized
Phase 3
No
Ceftaroline, Ceftriaxone
All
848
Interventional
18 Years - 150 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2014 by AstraZeneca
AstraZeneca
Forest Laboratories Inc
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Ceftaroline | Drug: Ceftaroline Two consecutive infusions q12h for 5 to 7 days |
Active Comparator: Ceftriaxone plus placebo | Drug: Ceftriaxone One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h. |